Skip to content

Effects of dietary fiber on glucolipid metabolism in gestational diabetes mellitus

Effects of dietary fiber on glucolipid metabolism in gestational diabetes mellitus

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200060117
Enrollment
Unknown
Registered
2022-05-19
Start date
2022-05-07
Completion date
Unknown
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gestational diabetes mellitus

Interventions

Low dose intervention group:Medical nutrition treatment and water-soluble dietary fiber 12g/d
Medium dose intervention group:Medical nutrition treatment and water-soluble dietary fiber 24g/d
Control group:Medical nutrition treatment

Sponsors

Qingdao Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. At 24-28 weeks of gestation, a 75g glucose tolerance test (OGTT) was performed, and the patients were diagnosed with gestational diabetes according to Guidelines for the Diagnosis and Treatment of Gestational Diabetes Mellitus (2014); 2. Single pregnancy; 3. Conventional medical nutrition treatment of blood glucose, without drug treatment of patients; 4. Voluntarily participate and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with serious systemic diseases requiring hospitalization; 2. Diabetic patients with pregnancy; 3. Patients with blood glucose treated with conventional medical nutrition and drug treatment; 4. Patients with incomplete data who have not received routine birth examination in our hospital; 5. Patients who have taken dietary fiber, probiotics or prebiotics within the last 1 month; 6. Patients who have a history of surgery to change the normal structure of the gastrointestinal tract, suffer from intestinal organic lesions, acute and chronic intestinal obstruction; 7. Patients with diseases deemed unsuitable for participation in this clinical trial by the investigator.

Design outcomes

Primary

MeasureTime frame
Glycosylated serum protein (GSP);

Secondary

MeasureTime frame
Glycosylated hemoglobin A1c (HbA1c);Fasting insulin (FINS);Fasting blood glucose (FBG);2h postprandial blood glucose (2hPBG);Total cholesterol (TC);Triglyceride (TG);Low density lipoprotein cholesterol (LDL-C);High density lipoprotein cholesterol (HDL-C);Intestinal flora abundance ;Wexner assessment score;Bristol Score;

Countries

China

Contacts

Public ContactGu Ping

Qingdao Municipal Hospital

13954278272@163.com+86 13954278272

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026